Azithromycin/Chloroquine

Small molecule

Azithromycin/Chloroquine is one of 61 small molecule programs targeting Plasmodium falciparum malaria. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Plasmodium Falciparum MalariaActive, not recruiting

MalariaActive, not recruiting

Plasmodium Falciparum MalariaPhase 2/Phase 3

Active, not recruiting

MalariaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

479 competitors in Malaria

#DrugCompanyPhaseTrials

Biltricide

Bayer

Preclinical

1 2

Stelara

Johnson & Johnson

Preclinical

—3

Hydroxychloroquine Sulfate

Novartis

Preclinical

—4

Iron

WWatson Pharmaceuticals

Preclinical

1 5

IV LBH589

Novartis

Preclinical

1 6

IV Ceftriaxone

RRESnTEC, Institute of Research

Preclinical

1 7

Mefloquine Plus Artesunate

Medicines for Malaria Venture

Preclinical

1 8

RTS,S/AS01E

GSK

Preclinical

4 9

Azithromycin/Chloroquine

Pfizer

Preclinical

3 10

Malarone

Medicines for Malaria Venture

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Malaria3 trials

Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia

Terminated· Pfizer logo

Pfizer·Phase 2/3·NCT00084240·32 enrolled

Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Malaria in Africa

Completed· Pfizer logo

Pfizer·Phase 2/3·NCT00082576·238 enrolled

Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India

Completed· Pfizer logo

Pfizer·Phase 2/3·NCT00074841·230 enrolled

Plasmodium falciparum malaria1 trial

Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America

Completed· Pfizer logo

Pfizer·Phase 2/3·NCT00084227·244 enrolled

Plasmodium Falciparum1 trial

Azithromycin in Combination With Chloroquine Versus Chloroquine in the Eradication of Asymptomatic Plasmodium Falciparum

Terminated· Pfizer logo

Pfizer·Phase 2·NCT00082563·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Azithromycin/Chloroquine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Azithromycin/Chloroquine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Azithromycin/Chloroquine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: Pfizer

Azithromycin/Chloroquine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Malaria3 trials

Plasmodium falciparum malaria1 trial

Plasmodium Falciparum1 trial

References

Drug Info

Quick Facts

Related News